Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based …
CJ Yang, MJ Tsai, JY Hung, TC Liu… - OncoTargets and …, 2016 - Taylor & Francis
Background Increased evidences show that epidermal growth factor receptor (EGFR)-
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …
The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line …
Background Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) such
as gefitinib can provide better efficacy and prolonged progression free survival (PFS) than …
as gefitinib can provide better efficacy and prolonged progression free survival (PFS) than …
Combination of chemotherapy and gefitinib as first‐line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: a randomized …
B Han, B Jin, T Chu, Y Niu, Y Dong, J Xu… - … journal of cancer, 2017 - Wiley Online Library
To explore the optimal treatment strategy for patients who harbor sensitive EGFR mutations,
a head‐to‐head study was performed to compare chemotherapy and gefitinib in …
a head‐to‐head study was performed to compare chemotherapy and gefitinib in …
Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive …
N Yoshimura, S Kudoh, S Mitsuoka, N Yoshimoto… - Lung cancer, 2015 - Elsevier
Purpose Patients with advanced non-small cell lung cancer (NSCLC) harboring a sensitive
epidermal growth factor receptor (EGFR) mutation have been shown to exhibit a marked …
epidermal growth factor receptor (EGFR) mutation have been shown to exhibit a marked …
Efficacy of platinum-based combination chemotherapy in advanced lung adenocarcinoma harboring sensitive epidermal growth factor receptor (EGFR) mutations with …
Background The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
eventually fails in treating advanced lung adenocarcinoma harboring sensitive EGFR …
eventually fails in treating advanced lung adenocarcinoma harboring sensitive EGFR …
Chemotherapy plus EGFR-TKI as first-line treatment provides better survival for advanced EGFR-positive lung adenocarcinoma patients: updated data and exploratory …
Y Lou, J Xu, Y Zhang, J Lu, T Chu, X Zhang, H Wang… - Targeted Oncology, 2020 - Springer
Background Previously, we demonstrated that treatment with gefitinib combined with
pemetrexed plus carboplatin chemotherapy improved progression-free survival (PFS) …
pemetrexed plus carboplatin chemotherapy improved progression-free survival (PFS) …
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
PURPOSE Standard first-line therapy for EGFR-mutant advanced non–small-cell lung
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …
Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes
X Jiang, B Yang, J Lu, Z Zhan, K Li, X Ren - Tumor Biology, 2015 - Springer
Advanced lung adenocarcinoma patients with epidermal growth factor receptor (EGFR)
activating mutations usually are highly sensitive to EGFR tyrosine kinase inhibitors (TKIs) …
activating mutations usually are highly sensitive to EGFR tyrosine kinase inhibitors (TKIs) …
The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A …
BC Wang, WX Zhang, BH Kuang, GH Lin - Plos one, 2022 - journals.plos.org
Background Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)
monotherapy is the standard of care in treating advanced non-small cell lung cancer …
monotherapy is the standard of care in treating advanced non-small cell lung cancer …
[HTML][HTML] Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
Objective Oral tyrosine kinase inhibitor has been shown to prolong progression-free survival
(PFS) in epidermal growthfactor receptor (EGFR) mutation positive adenocarcinoma; …
(PFS) in epidermal growthfactor receptor (EGFR) mutation positive adenocarcinoma; …
相关搜索
- egfr mutation lung adenocarcinoma
- egfr mutations clinical efficacy
- egfr mutation salvage therapy
- lung adenocarcinoma salvage therapy
- lung adenocarcinoma acquired resistance
- egfr mutation acquired resistance
- lung adenocarcinoma cytotoxic chemotherapy
- egfr mutations gefitinib treatment
- egfr mutation cytotoxic chemotherapy
- egfr mutation combination regimen
- clinical efficacy gefitinib treatment
- salvage therapy acquired resistance
- salvage therapy cytotoxic chemotherapy
- cytotoxic chemotherapy acquired resistance
- combination regimen gefitinib and pemetrexed
- egfr mutation gefitinib and pemetrexed